Solara Active Pharma Sciences Limited (SOLARA) fundamentals
Solara Active Pharma Sciences Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as SOLARA (ISIN INE624Z01016). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Solara Active Pharma Sciences Limited does
Solara Active Pharma Sciences Limited is an India-based global, pureplay active pharmaceutical ingredients (API) company. The Company is engaged in the manufacturing and development of APIs and offers contract manufacturing and development services for global companies. Its commercial product category includes Albendazole, Aprepitant (Antiemetic), Colchicine, Citicoline Sodium, Disulfiram, Dolutegravir, Etomidate, Flucytosine, Ibuprofen Arginine, Lurasidone Hydrochloride, Rifaximin, Tioconazole, Zileuton and others. Its research and development (R&D) product category includes Brivaracetam, Flecainide Acetate, Naproxen Base, Obeticholic acid, Patiromer Sorbitex Calcium, Rotigotine, Safinamide, Sapropterin, Sugammadex, Tranexamic Acid, Sucroferric Oxyhydroxide and others. Its business is spread across 70 countries with operations in the key markets of North America, Europe, Japan, South Korea and the Middle East and North Africa. It has one R&D center in Chennai.
Valuation and market data
| Last close | ₹749.15 |
|---|---|
| Market capitalisation | ₹3,304 crore |
| Enterprise value | ₹3,483 crore |
| P/E (TTM) | 0.00 |
| Price to book | 2.63 |
| Price to sales (TTM) | 1.37 |
| Book value per share | ₹284.66 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Jun 27 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹1,375 crore | ₹-7 crore | ₹-7 crore | -1.64 |
| Mar 2025 | ₹1,293 crore | ₹-1 crore | ₹-1 crore | -0.27 |
| Mar 2024 | ₹1,294 crore | ₹-488 crore | ₹-567 crore | -148.38 |
| Mar 2023 | ₹1,466 crore | ₹-45 crore | ₹-22 crore | -6.17 |
| Mar 2022 | ₹1,287 crore | ₹-92 crore | ₹-59 crore | -16.29 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 41.9% |
|---|---|
| Foreign institutions (FII) | 11.5% |
| Mutual funds | 0.9% |
| Other domestic institutions | 2.8% |
| Retail and others | 42.8% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.